ISRCTN87762302已完成3 期
A Phase III, randomized, open-label, comparator-controlled, parallel-group, multicenter study to compare the effects of exenatide and insulin glargine on beta-cell function and cardiovascular risk markers in subjects with type 2 diabetes treated with metformin who have not achieved target HbA1c
Eli-Lilly (The Netherlands)0 个研究点目标入组 75 人开始时间: 2005年12月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
2009 results in: https://www.ncbi.nlm.nih.gov/pubmed/19196887 (added 21/02/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with type 2 diabetes mellitus (m/f)
- •2. 30-70 years of age
- •3. Body mass index 25-40 kg/m2
- •4. Using stable (>2 months) oral anti-diabetic therapy with metformin alone
- •5. Subjects must have HbA1c between 6.6% and 9.5%, inclusive.
排除标准
- •1. Use of oral anti-diabetic therapy other than metformin
- •2. Clinical significant history or presence of hepatic, renal, central nervous system, gastrointestinal, haematological and pulmonary disease
- •3. Blood pressure >165/95
- •4. Electrocardiogram with clinically significant abnormalities as judged by the investigator
- •5. The use of prohibited medication as specified in the protocol
研究者
相似试验
已完成
3 期
A phase III, randomized, open-label, 500-subject clinical trial of minimally invasive surgery plus rtPA in the treatment of intracerebral haemorrhageISRCTN81927110Johns Hopkins University500
进行中（未招募）
不适用
A phase III, open-label, randomized, comparative study of the antiviral efficacy of ARV therapy with Lopinavir/Ritonavir (LPV/r - Kaletra) in combination with Tenofovir versus SOC (Kaletra in combination with 2 nucleoside RTIs) in naive HIV-1 positive patientsTreatment of HIV infection in naive HIV-1 positive patientsMedDRA version: 6.1Level: PTClassification code 10020162EUCTR2004-000786-35-ITABBOTT
进行中（未招募）
不适用
A Phase III study where Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections is compared with Iron Sulphate taken by mouth in subjects with non-dialysis dependent chronic kidney disease and with renal-related anaemia.on-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: LLTClassification code 10022974Term: Iron deficiency anemiaSystem Organ Class: 100000004851EUCTR2009-016728-29-ATPharmacosmos A/S350
进行中（未招募）
不适用
A Phase III study where Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections is compared with Iron Sulphate taken by mouth in subjects with non-dialysis dependent chronic kidney disease and with renal-related anaemia.on-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: LLTClassification code 10022974Term: Iron deficiency anemiaSystem Organ Class: 100000004851EUCTR2009-016728-29-IEPharmacosmos A/S350
进行中（未招募）
不适用
A Phase III study where Iron Isomaltoside 1000 (Monofer®) administered by infusions or repeated bolus injections is compared with Iron Sulphate taken by mouth in subjects with non-dialysis dependent chronic kidney disease and with renal-related anaemia.on-dialysis dependent chronic kidney disease and with renal-related anaemia (NDD-CKD)MedDRA version: 16.0Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 16.0Level: LLTClassification code 10022974Term: Iron deficiency anemiaSystem Organ Class: 100000004851EUCTR2009-016728-29-DKPharmacosmos A/S350